This clinical trial focuses on patients with localized prostate cancer who have high-risk features that make the cancer more likely to return after treatment. The study examines the effectiveness of combining different treatments: cabazitaxel (given as an intravenous infusion), pelvic radiotherapy, and hormone therapy (also known as ADT – Androgen Deprivation Therapy).
The purpose of this research is to determine if adding cabazitaxel treatment and radiation therapy to the pelvic lymph nodes can improve how long patients remain free from cancer progression when combined with standard hormone therapy and radiation treatment. The medication being studied, cabazitaxel (brand name Jevtana), belongs to a group of drugs called antineoplastic agents that are used to treat cancer.
During the study, participants will receive cabazitaxel through an intravenous infusion (delivered directly into a vein), along with radiation therapy to the pelvis area. The treatment period lasts approximately three months, and patients will be monitored for several years afterward to evaluate the long-term effects of the treatment combination. Throughout the study, doctors will track how well the cancer responds to treatment and monitor any side effects that may occur.
Belgium 
France 
Spain 
